公开(公告)号：US12110339B2

公开(公告)日：2024-10-08

申请号：US17103807

申请日：2020-11-24

Applicant: ALPINE IMMUNE SCIENCES, INC.

Inventor： Ryan Swanson ,  Michael Kornacker

IPC: C07K14/705 ,  A61K39/00 ,  A61P37/06 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/2896 ,  C07K14/70532 ,  C07K16/461 ,  C07K2317/40 ,  C07K2319/01

Abstract: Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

公开(公告)号：US20240327532A1

公开(公告)日：2024-10-03

申请号：US18645261

申请日：2024-04-24

Applicant: PROMETHEUS BIOSCIENCES, INC. ,  CEDARS-SINAI MEDICAL CENTER

Inventor： Jeffry D. Watkins ,  Cindy T. Dickerson ,  Rafael Rojas ,  Matthew Reissman ,  Patricia McNeeley ,  Janine Bilsborough ,  Bradley Henkle ,  Stephan R. Targan

IPC: C07K16/28 ,  A61P1/04 ,  C07K16/24

CPC classification number: C07K16/2875 ,  A61P1/04 ,  C07K16/241 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/76

Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

公开(公告)号：US20240309088A1

公开(公告)日：2024-09-19

申请号：US18392623

申请日：2023-12-21

Applicant: Genentech, Inc.

Inventor： Yvonne CHEN ,  Mark DENNIS ,  David DORNAN ,  Kristi ELKINS ,  Jagath Reddy JUNUTULA ,  Andrew POLSON ,  Bing ZHENG

IPC: C07K16/28 ,  A61K31/537 ,  A61K38/05 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  A61K51/10 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61K31/537 ,  A61K38/05 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6849 ,  A61K47/6867 ,  A61K51/1027 ,  C07K16/3061 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/92 ,  Y02A50/30

Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

公开(公告)号：US20240026033A1

公开(公告)日：2024-01-25

申请号：US18194276

申请日：2023-03-31

Applicant: Genentech, Inc.

Inventor： Yongmei Chen ,  James Ernst ,  Hok Seon Kim ,  Junichiro Sonoda ,  Christoph Spiess ,  Scott Stawicki ,  Yan Wu

IPC: C07K16/40 ,  C07K14/71 ,  C07K16/28

CPC classification number: C07K16/40 ,  C07K14/71 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/567 ,  C07K2317/71 ,  A61K2039/505

Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.

公开(公告)号：US11873341B2

公开(公告)日：2024-01-16

申请号：US16979932

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Sergio Quezada

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00 ,  C07K14/05

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/05 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US11814431B2

公开(公告)日：2023-11-14

申请号：US16814627

申请日：2020-03-10

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/53 ,  A61P35/00 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/2827 ,  A61P35/00 ,  C07K16/2818 ,  G01N33/57492 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US11807690B2

公开(公告)日：2023-11-07

申请号：US16655500

申请日：2019-10-17

Applicant: Genzyme Corporation

Inventor： Clark Pan ,  Huawei Qiu ,  Pradeep Dhal ,  Bo Chen ,  Diego Gianolio

IPC: C07K16/28 ,  A61K47/68 ,  A61K47/54 ,  C07K16/32 ,  C07K16/40

CPC classification number: C07K16/2893 ,  A61K47/549 ,  A61K47/6803 ,  A61K47/6869 ,  A61K47/6889 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/2851 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

公开(公告)号：US11795228B2

公开(公告)日：2023-10-24

申请号：US17489385

申请日：2021-09-29

Applicant: Dren Bio, Inc.

Inventor： Nenad Tomasevic ,  Ruo Shi Shi

IPC: C07K16/28 ,  A61K38/20 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2851 ,  A61K38/2013 ,  A61K39/3955 ,  C07K16/283 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77

Abstract: The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.

公开(公告)号：US11697688B2

公开(公告)日：2023-07-11

申请号：US16979935

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  James Geoghegan ,  Bianka Prinz ,  Sergio Quezada

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/55 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US11655492B2

公开(公告)日：2023-05-23

申请号：US17336975

申请日：2021-06-02

Applicant: R.P. Scherer Technologies, LLC

Inventor： David Rabuka ,  Gregory W. deHart ,  Patrick Holder ,  Jeanne Baker

IPC: C12P21/00 ,  A61K47/68 ,  C12N9/02 ,  C07K16/32 ,  C07K16/00

CPC classification number: C12P21/005 ,  A61K47/68 ,  A61K47/6889 ,  C07K16/00 ,  C07K16/32 ,  C12N9/0051 ,  C12P21/00 ,  C07K2317/14 ,  C07K2317/40 ,  C12Y108/99

Abstract: The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.